Non-small cell lung cancer metastatic
Not recruitingStudy Comparing Pembrolizumab Alone and with Sacituzumab Govitecan for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels
Study Comparing Pembrolizumab Alone and with Sacituzumab Govitecan for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels
- Disease:Non-small cell lung cancer metastatic
- Substances:Pembrolizumab
Germany- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Merck Sharp & Dohme LLC














